Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | HTR2B | P41595 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965627 | 1.00 | HTR2C (0.42) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL14091682 | 1.00 | HTR2C (0.42) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL3966291 | 0.90 | HTR2C (0.43) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL3966285 | 0.90 | HTR2C (0.43) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL14115776 | 0.79 | HTR2C (0.46) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL3966259 | 0.79 | ESR2 (0.39) | POLBKMT2AMEN1 | |
| SCHEMBL3966253 | 0.79 | ESR2 (0.39) | POLBKMT2AMEN1 | |
| SCHEMBL14091683 | 0.79 | ESR2 (0.39) | POLBKMT2AMEN1 | |
| SCHEMBL4792018 | 0.78 | HTR2C (0.40) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL3966494 | 0.76 | HTR2A (0.43) | HTR2CHTR2BHTR2APNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2B 7/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.